Graft-versus-host disease in mini-transplant

Shin Mineishi, Friedrich G. Schuening

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-transplant has drawn much attention as a surrogate marker for GVL/GVT effect. However, as the regimen-related toxicity is less in mini-transplant, it is also true that GVHD is the single most worrisome adverse event after mini-transplant. As opposed to early predictions, the incidence and severity of GVHD after mini-transplant does not seem to be much different from the one after conventional stem cell transplant (CST). In addition, researchers find that host antigen presenting cells (APC) may play an important role in the development of GVHD, and thus the existence of donor-host chimerism may be critical. As a result, the theory regarding GVHD after mini-transplant is getting more confusing. A comprehensive understanding of GVHD after mini-transplant is necessary.

Original languageEnglish (US)
Pages (from-to)1969-1980
Number of pages12
JournalLeukemia and Lymphoma
Volume45
Issue number10
DOIs
StatePublished - Oct 1 2004

Fingerprint

Graft vs Host Disease
Transplants
Leukemia
Neoplasms
Chimerism
Antigen-Presenting Cells
Stem Cells
Biomarkers
Research Personnel

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mineishi, Shin ; Schuening, Friedrich G. / Graft-versus-host disease in mini-transplant. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 10. pp. 1969-1980.
@article{75c904c746084d14853bdaae16dad6c3,
title = "Graft-versus-host disease in mini-transplant",
abstract = "Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-transplant has drawn much attention as a surrogate marker for GVL/GVT effect. However, as the regimen-related toxicity is less in mini-transplant, it is also true that GVHD is the single most worrisome adverse event after mini-transplant. As opposed to early predictions, the incidence and severity of GVHD after mini-transplant does not seem to be much different from the one after conventional stem cell transplant (CST). In addition, researchers find that host antigen presenting cells (APC) may play an important role in the development of GVHD, and thus the existence of donor-host chimerism may be critical. As a result, the theory regarding GVHD after mini-transplant is getting more confusing. A comprehensive understanding of GVHD after mini-transplant is necessary.",
author = "Shin Mineishi and Schuening, {Friedrich G.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1080/1042819042000219511",
language = "English (US)",
volume = "45",
pages = "1969--1980",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

Graft-versus-host disease in mini-transplant. / Mineishi, Shin; Schuening, Friedrich G.

In: Leukemia and Lymphoma, Vol. 45, No. 10, 01.10.2004, p. 1969-1980.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Graft-versus-host disease in mini-transplant

AU - Mineishi, Shin

AU - Schuening, Friedrich G.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-transplant has drawn much attention as a surrogate marker for GVL/GVT effect. However, as the regimen-related toxicity is less in mini-transplant, it is also true that GVHD is the single most worrisome adverse event after mini-transplant. As opposed to early predictions, the incidence and severity of GVHD after mini-transplant does not seem to be much different from the one after conventional stem cell transplant (CST). In addition, researchers find that host antigen presenting cells (APC) may play an important role in the development of GVHD, and thus the existence of donor-host chimerism may be critical. As a result, the theory regarding GVHD after mini-transplant is getting more confusing. A comprehensive understanding of GVHD after mini-transplant is necessary.

AB - Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-transplant has drawn much attention as a surrogate marker for GVL/GVT effect. However, as the regimen-related toxicity is less in mini-transplant, it is also true that GVHD is the single most worrisome adverse event after mini-transplant. As opposed to early predictions, the incidence and severity of GVHD after mini-transplant does not seem to be much different from the one after conventional stem cell transplant (CST). In addition, researchers find that host antigen presenting cells (APC) may play an important role in the development of GVHD, and thus the existence of donor-host chimerism may be critical. As a result, the theory regarding GVHD after mini-transplant is getting more confusing. A comprehensive understanding of GVHD after mini-transplant is necessary.

UR - http://www.scopus.com/inward/record.url?scp=4544270616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544270616&partnerID=8YFLogxK

U2 - 10.1080/1042819042000219511

DO - 10.1080/1042819042000219511

M3 - Review article

C2 - 15370240

AN - SCOPUS:4544270616

VL - 45

SP - 1969

EP - 1980

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -